Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
about
Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritisImmunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center CohortInfluence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome.Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodiesAntiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α.A De Novo Arisen Case of Primary Adrenal Insufficiency in an Adolescent Patient With Crohn Disease: A Case report.Infliximab for the treatment of ankylosing spondylitis.The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications.Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agentsThe role of tumor necrosis factor-alpha in systemic lupus erythematosusThe environment and antiphospholipid syndrome.Autoantibody production in anti-TNF-alpha-treated patients.The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis.Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab.Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo ClinicDrug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review.Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis.Drug-induced lupus anticoagulants and antiphospholipid antibodies.A systematic review of biologics for the treatment of noninfectious uveitis.Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis.Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus.Antinuclear antibody (ANA) testing in patients treated with biological DMARDs: is it useful?MPO-ANCA-associated necrotizing glomerulonephritis in rheumatoid arthritis; a case report and review of literature.Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro.Etanercept and venous thromboembolism: a case series.Trouble with tumor necrosis factor alpha inhibitors, not just tuberculosis.Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha.Persistent high levels of IgM antiphospholipid antibodies in a patient with recurrent pregnancy losses and rheumatoid arthritis.Thrombophlebitis of cephalic vein in the left forearm related to infliximab infusion.Infliximab for rheumatoid arthritis.Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
P2860
Q28218493-E016E335-B84B-48A0-94B4-39364CBC9924Q28554222-6999A7BD-363A-4659-9C78-2DE394E6606DQ30240229-2844C9E8-A357-4568-9155-5A1208CF43F2Q33737258-1CA2A289-B204-4BEC-A658-F43DC68594D5Q33934927-383DBA9B-08D8-4A8D-947C-AC1CFA64A146Q33944344-FC720243-34B7-4E55-AB95-17A00B7E6748Q34896439-8F0FC40D-E2FF-44DC-B1D7-7139E7CAB8A0Q35808834-DC58A791-C794-4BF7-BDBA-9C24118A5CE9Q36194145-05DA4DC0-2498-4710-8EAB-912CE2A53015Q36210882-ED46286E-6362-4CAF-9D8B-B4C2AF5D265AQ36373315-0DF5E3D0-3D3D-46BC-A36D-C10AC5659CB4Q36579988-4FAA586C-2EF0-481B-A795-A28430A07235Q36641608-471635ED-FCC8-47BD-B2A1-D07E77F888AEQ36677026-D0AD4CC3-8A87-4C93-A27A-2C786BCBC56DQ36958337-13C198C2-1059-4166-B669-9A7F09C8122EQ37196596-DE109529-B735-49DD-BD7E-782D19597F0FQ37270902-B432CA95-0458-49F3-BD02-8EE2BC88F85FQ37290665-F11B6E2B-83D6-4DFA-B5FC-E6D3735F4216Q37406698-0652F239-1F8E-4DD7-BC81-56148AA2DE7AQ37718987-246E63F8-B1B9-488C-991B-946DA0F45789Q37728019-8E268D07-D692-4FE5-B5F7-39220C635BECQ37967416-56B20AB5-870D-47AB-9F6B-27C7719B4A0BQ38068969-98A31491-5DFE-4860-A94C-B9E15A9F0C00Q38104769-FC2B8263-76F7-447A-9A61-7BA9AD814201Q38161813-DC1FC122-1AF8-49A6-A9AE-E8CFF211F6AAQ38411852-B61BB0AD-0625-40B2-BC72-05569514660CQ39297333-76A0C10E-0350-4A53-A256-0977A014A422Q41901439-721F148C-F61C-46F5-AEAD-A524B219A634Q42917322-A6CA7E1D-013A-429A-A2E8-9E1BBD692C6BQ43035866-3B55A481-E805-4605-908D-DD8BCADBB140Q46182117-43FAC5E2-1B08-43BA-9C3A-B66B5EE9D8D3Q50866340-65231C96-3F3D-4E40-896E-4966A47CB7C2Q51532185-6778FFCA-497F-4A58-ABBC-B90C3620C58AQ52856626-A06B8CAC-07A4-4732-89DD-D8D8C9DA4254Q53845804-C3C9E5A0-67A8-48B1-846E-DCE7D49E80F6
P2860
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Infliximab therapy in rheumato ...... : a two-year prospective study
@ast
Infliximab therapy in rheumato ...... : a two-year prospective study
@en
Infliximab therapy in rheumato ...... : a two-year prospective study
@nl
type
label
Infliximab therapy in rheumato ...... : a two-year prospective study
@ast
Infliximab therapy in rheumato ...... : a two-year prospective study
@en
Infliximab therapy in rheumato ...... : a two-year prospective study
@nl
prefLabel
Infliximab therapy in rheumato ...... : a two-year prospective study
@ast
Infliximab therapy in rheumato ...... : a two-year prospective study
@en
Infliximab therapy in rheumato ...... : a two-year prospective study
@nl
P2093
P2860
P3181
P356
P1476
Infliximab therapy in rheumato ...... : a two-year prospective study
@en
P2093
Carole Ferraro-Peyret
Fabienne Coury
Jacques Bienvenu
Jacques G Tebib
Nicole Fabien
P2860
P2888
P304
P3181
P356
10.1186/AR1440
P407
P577
2004-09-23T00:00:00Z
P5875
P6179
1002715575